Tyler Kristoff

Dr. Tyler Kristoff

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in American Journal of Clinical Oncology
Verified
Journal Article
Open access
RPRobin Park
Robin Park
FRFahad Rind
Fahad Rind
TKTyler Kristoff
Tyler Kristoff
JLJiannong Li
Jiannong Li
MSMichael Schell
Michael Schell
CCChristine Chung
Christine Chung
Objectives: We report on the biomarker analyses focusing on neutrophil-to-lymphocyte ratios (NLR) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with combined cetuximab and nivolumab. Methods: Data were obtained from a phase II trial (NCT03370276). Peripheral blood NLR was obtained at baseline (B-NLR) and on-treatment (OT-NLR; 1 mo from treatment initiation). Tumor NLR (T-NLR) was determined by staining of immune cells in primary tumors. Patients were stratified into high (≥median) or low NLR (<median). The association between NLR with survival outcomes was evaluated. Results: While B-NLR did not correlate with survival or responses, low OT-NLR was associated with superior overall survival (OS; P <0.0001), progression-free survival (PFS; P =0.0002), and overall response ( P <0.001) compared with high OT-NLR. Multivariable analysis further demonstrated that low OT-NLR was associated with superior OS (HR 0.32, 95% CI, 0.17-0.61) and PFS (HR 0.45, 95% CI, 0.25-0.81). Compared with patients with high OT-NLR, a higher proportion of patients with low OT-NLR had OS≥24 months ( P =0.0001). Low OT-NLR was associated with higher baseline PD-L1 combined positive scores ( P =0.037). Low pretreatment T-NLR was associated with superior OS and PFS in multivariable analysis and correlated with superior overall response ( P =0.011). Conclusions: Low OT-NLR and pretreatment T-NLR correlated with superior treatment outcomes in patients with R/M HNSCC treated with cetuximab and nivolumab. Further evaluation of T-NLR to improve patient selection and peripheral blood OT-NLR as a dynamic biomarker contributing to clinical benefit assessment given cetuximab and nivolumab is warranted.